FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to therapy, and can be used for treating arthritis in a mammal, involving administering N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulphanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulphonyl)benzene sulphonamide (ABT 263).
EFFECT: invention provides treating arthritis by specific lymphocytic immune suppression in a patient caused by administering the above compound.
3 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING ARTHRITIS | 2008 |
|
RU2472509C2 |
METHOD OF OBTAINING APOPTOSIS STIMULATOR ABT-263 | 2009 |
|
RU2514935C2 |
BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR TREATING CANER AND IMMUNE DISEASES | 2010 |
|
RU2542994C2 |
APOPTOSIS INDUCING AGENTS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2538965C2 |
APOPTOSIS-INDUCING PREPARATIONS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2009 |
|
RU2527450C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2535203C2 |
APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF BCL-2 FAMILY INHIBITOR | 2010 |
|
RU2711359C2 |
APOPTOSIS-INDUCING MEDICATIONS FOR TREATING CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2554346C2 |
APOPTOSIS-INDUCING AGENTS FOR TREATING MALIGNANT TUMOURS AND IMMUNE AND AUTOIMMUNE DISEASES | 2010 |
|
RU2573832C2 |
Authors
Dates
2014-08-20—Published
2008-11-14—Filed